Boston Scientific Corporation (BSX)
The TAVR Pioneer Bets Everything on One Market as Its Competitor Spreads Risk
Edwards Lifesciences (NYSE: EW) and Boston Scientific (NYSE: BSX) both reported strong quarters, but the results reveal fundamentally different strategies in the heart device market.
What Happened To Boston Scientific Stock?
Boston Scientific (BSX), a leading global player in medical devices, announced solid Q4 earnings but offered 2026 guidance that slightly fell short of elevated investor expectations. This response was marked by a drastic, high-volume liquidation event that quickly erased months of gains.
Why Boston Scientific (BSX) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Boston Scientific Corporation (BSX) Q4 2025 Earnings Call Transcript
Boston Scientific Corporation (BSX) Q4 2025 Earnings Call Transcript
BSX Stock Dips in Premarket Trading Despite Q4 Earnings, Revenue Beat
BSX beats Q4 EPS and revenue estimates and lifts margins, but shares slide 9.1% in pre-market as investors weigh outlook and guidance.
Boston Scientific (BSX) Reports Q4 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Boston Scientific (BSX) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Boston Scientific Profit, Sales Rise but Issues Soft Guidance
Sales rose 16%, but the medical-device maker issued a soft forecast for the year, sending shares down premarket.
Boston Scientific (BSX) Beats Q4 Earnings and Revenue Estimates
Boston Scientific (BSX) came out with quarterly earnings of $0.8 per share, beating the Zacks Consensus Estimate of $0.78 per share. This compares to earnings of $0.7 per share a year ago.
Boston Scientific Earnings Beat Expectations. Why the Stock Is Down Sharply.
The medical-device maker beats quarterly earnings expectations but offers a disappointing outlook for the current quarter.
Boston Scientific (BSX) Q4 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Beyond analysts' top-and-bottom-line estimates for Boston Scientific (BSX), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2025.
Will Robust MedSurg Performance Fuel Boston Scientific's Q4 Earnings?
BSX heads into Q4 earnings with strong MedSurg momentum and Cardiovascular growth, as revenue and EPS estimates point to double-digit gains.
Boston Scientific (BSX) Exceeds Market Returns: Some Facts to Consider
In the closing of the recent trading day, Boston Scientific (BSX) stood at $92.51, denoting a +1.34% move from the preceding trading day.
